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Cystic echinococcosis (CE) is a widespread chronic endemic helminthic disease caused by infection with metacestodes of the
tapeworm Echinococcus granulosus.C Ea ﬀects humans and has a worldwide prevalence of approximately six million. In this review,
we discuss current ﬁndings in diagnosis and clinical management of CE and new concepts relating to E. granulosus molecules that
directly modulate the host immune responses favouring a strong anti-inﬂammatory response and perpetuating parasite survival
in the host. New insights into the molecular biology of E. granulosus will improve considerably our knowledge of the disease and
will provide new potential therapeutic applications to treat or prevent inﬂammatory immune-mediated disease.
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1.Introduction
Although eﬀective preventive and therapeutic measures
have been developed for most parasitic helminths, cystic
echinococcosis (CE) infection is still very common in the
developing world today. CE, a widely chronic endemic
helminthic disease caused by infection with metacestodes
(larval stage) of the tapeworm Echinococcus granulosus,i s
one of the most widespread Helminth zoonotic diseases
in humans [1–5]. E. granulosus metacestode infections are
characterized by the development of slowly growing hydatid
cysts which may not be detected for months or years
after the initial infection has occurred. The persistence of
these cysts is of interest to immunologists since, once fully
formed, they are apparently unaﬀected by the hosts immune
response. The host parasite relationship is interactive and
the outcome of infection depends on the balance achieved
by the combination of the diﬀerent variables involved with
the host immunity and the parasite avoidance strategies.
An understanding of the biological events occurring during
infection is necessary to visualize the diverse immune stimuli
to which the host is subjected and to deﬁne diagnostic and
therapeutic tools. The evidence suggests that the interme-
diate hosts respond independently to antigenic stimuli of
the invading oncosphere, the metacestode in transformation
from the oncosphere, and ﬁnally, the mature metacestode
(larvae) [6].
The oncospheres hatch and become activated in the
small intestine when a suitable intermediate host ingests
Echinococcus eggs. Lytic secretions of the oncosphere then
facilitate its passage through the intestinal mucosa and into
the host circulatory system (venous and lymphatic) through
which they are distributed to the liver, lungs, and other
sites where postoncospheral development continues. Within
a few days after, oncospheres reach the preferred site, cystic
development begins. This process involves degeneration of
the oncospheral stage and emergence of the metacestode
stage. In vitro 4–7 days are required for larvae to change
into a typical “bladder” with a germinal layer. Subsequently,
development time varies widely from one host species to
another. In general, hydatid cysts increase in diameter from
lessthan1to5cmeachyear.Thematurehydatidcystconsists
of an inner germinal layer of cells supported externally by an
acellular-laminated membrane of variable thickness. Tegu-
mental cells of the germinal layer unite to form a continuous
syncytium which is diﬀerentiated into numerous microvilli
that project peripherally into the laminar layer toward the
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cysts called “brood capsules” bud internally from the germi-
native layer and, by asexual reproduction, produce multiple
protoscoleces that can diﬀerentiate either into adult worms
in the intestines of deﬁnitive hosts or into secondary hydatid
cysts following rupture of a cyst in the intermediate hosts.
Because the oncosphere is known to be associated with
the protective immune response, understanding the mecha-
nisms, whereby protective antibodies against the oncoshere
act, is of fundamental importance in developing highly
eﬀective vaccine against E. granulosus [6]. A vaccine based
on the recombinant oncosphere protein, Eg95, has been
produced for prevention of infection in the parasite’s natural
animal intermediate hosts [7, 8].
2. ClinicalAspects: Diagnosisand Therapy
Despite the advances in modern imaging and therapeutic
strategies, problems associated with the diagnosis and treat-
ments of human CE are still challenging and often diﬃcult
to resolve. Early diagnosis is important, because prompt
intervention enables eﬃcient management and treatment of
the disease and results in reduced morbidity and mortality.
Initially, cysts are small and patients are asymptomatic [9,
10]. Cysts in such instances are too small, too young, to
pose clinical problems; usually they are single and localized
in a neutral space in liver or lungs. The cysts may heal
spontaneously by inconspicuous rupture and evacuation,
or by degenerative and/or necrotic processes leading to a
solidiﬁcation and/or calciﬁcation of the cysts. Apart from
lung cysts, which are more often symptomatic also if they are
very small, symptomatic cases of CE are usually those with
the cyst’s diameter >5cm. In most cases initially, the clinical
diagnosis of CE is diﬃcult and requires, beside the physical
examination, imaging techniques and serology [11, 12]. As
the cysts grow, however, they can exert mechanical pressure
on surrounding organs and can cause several pathological
changes mediated by compression or obstruction. Large
amounts of hydatid ﬂuid, after cyst rupture, can result
in anaphylactic reaction that varies widely from benign
urticaria and short episodes of shaking chills and/or fever, to
a potentially fatal bronchial spasm, angioneurotic oedema,
and anaphylactic shock. Cyst rupture can also result in a
secondary hydatid infection caused by the release of many
thousands of protoscoleces, which each have the potential to
diﬀerentiate into another hydatid cyst.
Introduction of ultrasound (US) in the late 1970s has
greatly improved the detection of liver and abdominal
Echinococcus cysts and diﬀerential diagnosis from common
nonparasitic true cysts and pseudocysts of traumatic, degen-
erative, inﬂammatory, and malignant origin. In particular,
thisnoninvasive,low-risk,andlow-costexaminationcanalso
have a positive educational eﬀect in endemic communities
[13]. The combination of US and conﬁrmatory serology is
now a standard approach for clinical and epidemiological
surveys [14]. Whereas hepatic cysts can be preferentially
diagnosed by US, hydatid cysts localized in lungs or in other
organsthanliverandabdomencanbesuccessfullydiagnosed
by computerized tomography (CT) or Nuclear Magnetic
Resonance imaging (NMR). In 2001, the WHO Informal
WorkinggrouponEchinococcosisproposedaninternational
classiﬁcation of hepatic cysts based on US morphology
correlated to the activity of the disease [10, 15]. Following
the WHO classiﬁcation, hepatic hydatid cysts are grouped
into ﬁve major cyst types, CE1-CE5, characterized by the
appearance of the cyst contents and wall. Using such clas-
siﬁcation has enabled clinicians to examine recommended
clinical procedures for the diﬀerent cyst types. If “Cystic
Lesions” are deﬁned as suspicious lesions, and if due to CE,
then these cysts are usually at an early stage of development
and are not fertile. Type CE1 (unilocular, simple cysts)
and type CE2 (multivescicular, multiseptated cysts) are
considered as active since they are likely to contain viable
protoscoleces. Type CE3 (unilocular cysts with detachment
of laminated membrane or multiseptated cysts with partial
hyperechoic content) are considered as transitional and
might represent the beginnings of cyst degeneration. Type
CE4 (heterogeneous or hyperechoic degenerative contents)
and type CE5 (calciﬁed cysts) are considered inactive, as the
parasite tissue is likely to be of low viability. Actually, we
can consider the current WHO classiﬁcation as a progressive
natural history of cyst development from CE1 to CE5. It is of
huge importance to understand the possible developmental
fateofacyst,butUSimagingalonecannotpredicttheclinical
fate of a cyst. Cysts classiﬁed by US as identical in clinical
type may have distinctly diﬀering fates: some will ultimately
progress whereas others will regress (mainly, types CE3 and
CE4). New interesting observation on the immunological
mechanisms underlying these distinct outcomes indicate
that the serologic proﬁle associated with cysts of the same
ultrasonographic type (type CE 3-4-5) correlates with the
fate of the cyst: higher IgG1 and IgG3 in stable disease and
higher IgG4 and IgE in progressive disease [16]. Because
the advanced diagnostic techniques used today, for example,
ultrasound scanning, detect even young (early stage) cysts
(less than 2cm in diameter) and calciﬁed (late stage) cysts,
providing more sensitive serological tests which are still a
pressing research aim. In fact, a key problem for immunodi-
agnosis is the increasing numbers of seronegative patients or
low responders, who still have too few antibodies detectable
by serologic tests. To overcome problems of cross-reactions
with other parasite antigens in countries with endemic
disease, it is important to have new more antigens that are
speciﬁc. The correct diagnosis of CE involves clinical, labo-
ratory, and epidemiological information. As far as possible,
alternative diagnostic methods are obligatory for suspected
CE images in the US [10]. In fact, without conﬁrmation
of immunological tests, clinical and/or imaging technique
diagnosis is not certain, unless for histological and/or
cytological examination, being CE cysts hardly distinguished
from “space occupying lesions” [5, 17]. Immunodiagnosis
is useful not only for the primary diagnosis but also for
the follow-up of patients after surgical or pharmacological
treatment, or both [10, 17]. Hydatid serological testing has
a long history and almost all serological tests that have
been developed have been used in the diagnosis of human
cases. The choice of a serodiagnostic technique depends
primarily on its sensitivity and speciﬁcity. The ﬁrst problem
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false-negative results (up to 25%). Secondly, false-positive
reactions are present in areas where E. granulosus and E.
multilocularis coexist and in areas where other parasitic
diseases are endemic. An optimum test should be speciﬁc
with high sensitivity. Immunodiagnostic techniques include
initial screening tests, using crude antigens, such as latex
agglutination, double diﬀusion, indirect hemagglutination,
and enzyme-linked immunosorbent assay, followed by con-
ﬁrmatory tests using speciﬁc antigens, for example, arc-5
immunoelectrophoresis and immunoblotting [11, 12]. In
particular, immunoblotting technique uses antibodies to
identify speciﬁc target proteins and is now widely employed
inroutinelaboratoryapplicationsfortheanalysisofimmune
responses [5]. Another diagnostic strategy for identifying
active or current infections is to develop a technique for
detecting circulating antigen in serum and urine [18, 19].
The history of immunodiagnosis represents the history
ofEchinococcusantigensbecausethechoiceofanappropriate
source of antigenic material is a crucial point in the immun-
odiagnosis [5]. As the intermediate host of E. granulosus,
humans are exposed to a variety of antigenic determinants
on parasite-derived or parasite-modiﬁed molecules; each
of these various sources of antigenic stimulation may be
relevant to immunodiagnosis. The repertoire of antigens to
whichthehostisexposedincludesmanyfactors,forexample,
the species or strain of parasite, host immunocompetence,
organ parasitised, cyst fertility, cyst viability, and integrity
of the cyst wall [20]. Antigens derived from Echinococcus
oncospheres have not yet been successfully adapted to
immunodiagnostic tests; however, such antigens provide
theoretical advantages over metacestode stage antigens for a
variety of purposes, including early detection of infection.
Extensive studies have focused on hydatid ﬂuid antigens
that still represent the main antigenic source for hydatid
disease diagnosis. At the present time, the parasitic antigens
present in hydatid ﬂuid that have major immunodiagnostic
value in detecting E. granulosus are antigen 5 (Ag5) and
antigen B (AgB) [21]. Native Ag5, a 400kDa thermolabile
lipoprotein produces two subunits at 55 and 65kDa in
sodium-dodecyl sulphate-polyacrilamide gel electrophore-
sis (SDS-PAGE) under nonreducing conditions and two
subunits at 38/39 and 20kDa under reducing conditions
[22, 23]. The 38/39kDa component with phosphorylcholine
epitopes may be responsible for a large proportion of cross-
reactions with sera from patients infected with nematodes,
cestodes, and trematodes [24–26]. Native AgB, a 160kDa
thermostable lipoprotein, produces three main subunits at
8/12, 16, and 20kDa in SDS-PAGE under reducing and
nonreducing conditions as well as other mass-subunits,
probably polymers of the 8/12kDa subunit [27]. The
8/12kDa subunit induces a good humoral and cellular
response [28]. Even though the 8/12kDa subunit of AgB
is cross-reactive in a high-percentage patients with alveolar
echinococcosisseraandinasmallpercentageofpatientswith
cysticercosis, native AgB is of high immunodiagnostic value
[21, 24, 29].
To overcome some problems several recombinant anti-
gens have been produced and used as molecular tools in
the immunodiagnosis of CE [5, 30]. Although a few studies
have assessed the diagnostic usefulness of recombinant
Ag5 intense research has evaluated recombinant AgB and
synthetic peptides that could be used in immunodiagnosis
of CE [30–32]. To date, the only peptide that has proved
diagnostic is that derives from the sequence of EgAgB1p176
[33].Althoughnativeandrecombinantantigensyieldsimilar
sensitivity, both have advantages and disadvantages [31].
Native antigens have to be extracted from the various
sources, puriﬁed and prepared for use in each laboratory.
They are, therefore, of limited availability, and nonstan-
dardized in quality and composition. Recombinant antigens,
usually commercially prepared and then distributed to the
various diagnostic centres, have the advantage of being
standardized in quality and composition.
For many years, surgery has been considered the only
treatment available for CE because of the potential radical
removing of the parasite. Nowadays, besides surgery, clin-
ical management of CE may relies on several therapeutic
approaches ranging from chemotherapy with benzoimida-
zole carbamates (mebendazole and albendazole) to percu-
taneous nonconventional treatment, like PAIR, or Radio-
Frequency Thermoablation, or “wait and see” approach [9].
New guidelines on clinical management of liver CE suggest
thatthereisnotasingle“goldenrule”butitisveryimportant
to individualize the treatment of choice for each patient and
for each hydatid cyst [9, 13, 34, 35] .As e r i e so fe a r l ya r t i c l e s
have comprehensively reviewed the clinical management of
CE[9,13,36,37].Here,weconsiderthemorerecentprogress
in the clinical management during hepatic involvement of
CE. In the therapeutic approach to liver CE, it is advisable
to distinguish the cases in which there is a concordance
between clinical and serological data and imaging ﬁndings,
and the cases in which these ﬁndings are discordant. In
the ﬁrst cases, and for no complicated small hepatic cysts
(of diameter <5cm, CE4-CE5 type), it is possible to take
into account the “wait and see” approach because inactive
cysts that do not compromise organ function or cause
discomfort, seem to remain like this or stabilize even further.
When clinical, immunological data and US ﬁndings are
not concordant or when the cysts are complicated, surgery
represents the ﬁrst choice treatment [9, 13]. Surgery is
indicated for large hepatic cysts with multiple daughter cysts;
for single hepatic cysts, situated superﬁcially, which may
rupture spontaneously, or because of trauma; for cysts that
areinfected;forcystscommunicatingwithbiliarytreeand/or
exerting pressure on adjacent vital organs. Because curative
surgeryis notalwayspossible, thereisa2–15% riskofrelapse
in hyperendemic areas and moderate ranges of morbidity
in particular when the surgery is repeated. During surgery,
the cyst can break spontaneously or the surgical damage of
the cyst can lead to spillage and widespread dissemination
[9, 36, 37].
Chemotherapy with benzoimidazole carbamates (mebe-
ndazole or albendazole), once reserved for inoperable cases
of CE, is now more widely used [34, 37–41]. Benzamidazole
carbamates inhibit tubulin and induce blockage of glucose
absorption, glycogen depletion, and degenerative modiﬁca-
tions in the endoplasmatic reticulum and in mitochondria
of the germinal layer increasing lysosomes and producing4 Interdisciplinary Perspectives on Infectious Diseases
cellular autolysis [41]. Mebendazole and albendazole have
the same mechanism of action; albendazole shows a better
pharmacokinetic proﬁle reaching higher plasmatic concen-
trations than mebendazole. At present, a cycle of albendazole
treatment can be suggested as ﬁrst choice treatment in
patients with no complicated cysts and in patients with-
out contraindications to chemotherapy (pregnancy, marked
impairment of liver, renal or haemopoietic functionality).
Most of the cysts treated with benzoimidazole carbamates
show degenerative modiﬁcations (volumetric reduction
and/or morphological alterations, such as solidiﬁcation,
detaching of membranes, and calciﬁcation) whose further
evolution can hardly be predicted: in some cysts these
degenerative modiﬁcations progressed until the parasite’s
death (biological recovery), while some cysts recurred after
the end of treatment. Apart quantitative diﬀerences due to a
more eﬀectiveness of albendazole for hepatic cysts, albenda-
zole, and mebendazole show similar eﬀects. Treatment with
benzoimidazolecarbamatesiseﬀectiveandwelltoleratedbut
can be aﬀected by many factors related both to the host
and to the parasite. Both albendazole and mebendazole are
more eﬀective in cycles of continuous treatment, without
intervals. It is relevant to note that young cysts and cysts
of young people are more responsive, probably because
these cysts present a higher metabolic activity and a greater
susceptibility to the drugs. Benzoimidazole carbamates are
more eﬀective against cysts in the lung than against cysts in
the liver that may be because of their thinner membranes.
Regarding the type of hepatic cysts, CE1 cysts frequently
showmembranedetachmentaftertreatment,whileCE2cysts
frequently show matrix solidiﬁcation. Sometimes cysts of
the same patient with the same morphology and localized
in the same organ may diﬀerently respond to therapy
probably because have a diﬀerent intrinsic sensitivity to
drugs. Some treated patients’ exhibit relapses, but these
are usually sensitive to retreatment in high proportion of
cases (up to 90%) [42]. Chemotherapy with benzoimidazole
carbamates appears to be safe and well tolerated, the main
adverse events are to changes in transaminases (<5-fold the
normal range), observed in about 15% of the patients. To
note,thisside-eﬀectisreversible,becausetransaminasevalue
returned to normal without stopping treatment and it was
mainly observed in patients with hepatic cysts and eﬀec-
tiveness of therapy [37, 43]. The increase in transaminases
may be caused by the inﬂammatory immune response to
the antigenic spillage from the hepatic cysts damaged by
benzimidazole carbamates, and because correlates with the
eﬀectiveness of therapy could be considered as a prognostic
marker. This ﬁnding further supports the importance of
immune-mediate mechanisms in the clinical outcome of
chemotherapy of CE, as observed for antibiotic treatment
and innate and cell-mediated immunity. Because there is
no doubt that, as an adjuvant therapy, chemotherapy can
signiﬁcantly contribute to the successful management of CE,
the search for new drugs is ongoing [44].
In the last two decades, the percutaneous treatment
by Puncture of the cyst, Aspiration of cyst ﬂuid, Injection
of a scolicidal agent, and reaspiration of the cyst con-
tent percutaneous (PAIR) under sonographic guidance has
gained an important role in the treatment of CE; its eﬃcacy
has been conﬁrmed both by short- and long-term follow-
up. The aim of this treatment is to destroy the germinal
layers with scolicidal agents or to evacuate the germinal
and laminated layers, that is, the entire endocyst [45].
Percutaneous drainage of echinococcal cysts is eﬀective and
safe, as shown by the very low complication rate. Because
neither imaging modalities nor serology is suﬃcient to assess
directly the presence of parasites in the cyst, PAIR is the only
method providing a direct diagnosis of the parasitic nature
of the cysts. The major risks of percutaneous techniques
are anaphylactic shock, secondary echinococcosis caused by
spillage of cystic ﬂuid, and chemical colangitis caused by
contact of the scolicidal agent with the biliary tree.
Radiofrequency thermal ablation uses the same needle
electrodes used for local treatments or hepatocellular car-
cinomas [46]. The experience with radiofrequency thermal
ablation is still very limited; however, it does not seem to be
very eﬀective at long-term follow-up [13].
3. New PromisingPerspectivesfrom the
Host-ParasiteRelationship
Evidence from epidemiological studies indicates an inverse
correlation between the incidence of certain immune-
mediated diseases, including inﬂammatory bowel disease,
and exposure to Helminth. Helminth parasites are the
classic inducers of anti-inﬂammatory Th2 responses. Cross-
regulatory suppression of the Th1 responses by a strong
Th2 response has a role in modulating diseases characterized
by a Th1 response. In particular, the Th2-polarized T cell
response driven by Helminth infection correlates with the
attenuation of some damaging Th1-driven inﬂammatory
responses, preventing some Th1-mediated autoimmune dis-
eases in the host [47–49].
Current evidence concerning antibody levels of IgG4 and
IgE isotypes and frequent eosinophilia in CE suggests that
the immune response to established E. granulosus infection
is Th2 dominated and that Echinococcus antigens modulate
polarized T-cells. These observations received conﬁrmation
fromstudiesshowingthatthehumanimmuneresponsetoE.
granulosus infection is predominantly regulated by Th2 cell
activation (in vitro production of IL-4, IL-5, IL-6, IL-10 by
PBMC isolated from patients with CE) and also by the Th1
(or Th0) cell subset (IFN-γ production) [50]. Many ﬁndings
indicated that in CE a strong Th2 response correlates with
susceptibility to disease (active cyst), whereas a Th1 response
correlates with protective immunity (inactive cyst) and that
Th1 and Th2 responses coexist [6, 50, 51].
DuringCE,thedistinguishingfeatureofthehost-parasite
relationship is that chronic infection coexists with detectable
humoral and cellular responses against the parasite. E.
granulosus could use two mechanisms to subvert the host
immune response: passive escape, in which the parasite,
by developing into a hydatid cyst, avoids the damaging
eﬀects of an immune response, and immunomodulation,
through which the parasite actively interacts with the host
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[12]. Recent studies demonstrated that E. granulosus secretes
several molecules present in protoscoleces and in hydatid
ﬂuid that directly can modulate the immune responses thus
altering the cytokine balance towards Th2 and favouring
their evasion and perpetuating their survival in the host [52–
54]. These molecules interfere with antigen presentation, cell
proliferation and activation, antibody production, cause cell
death, and stimulate regulatory responses.
The abundance of AgB in hydatid ﬂuid suggests that this
antigen has an important biological role in E. granulosus
infection. AgB is involved in modulating the host immune
response altering both innate and adaptative host immune
responses. The 12-kDa subunit of AgB is a protease inhibitor
that can inhibit neutrophil recruitment and that has a
critical role in parasite escape mechanisms from early
natural immunity [55]. Investigating further, the role of AgB
in the host-parasite relationship has been conﬁrmed that
AgB impairs the inﬂammatory response and inﬂuences the
Th1/Th2balancetowardsaTh2polarization[56].Tonote,E.
granulosus AgB acts to escape the host immune response by
interfering directly with host dendritic cell function through
two strategies [57]. First, it impairs monocyte precursor
diﬀerentiation into immature dendritic cells rendering them
unable to mature when stimulated with LPS; secondly, AgB
modulates sentinel dendritic cells maturation, priming them
to polarize lymphocytes into Th2 cells.
The possibility that IgG subclasses from patients with
active or inactive CE might contain antibodies against
molecules involved in the host-parasite interaction has been
extensively examined [58]. In vitro AgB driven Th2 cytokine
production corresponds in vivo to elevated speciﬁc IgE
and IgG4 antibody binding to the 8 kDa subunit of AgB
[16, 58, 59]. A new immunomodulating antigen has been
obtained by screening an E. granulosus cDNA library with
IgG4 from patients with active disease: a protein localized
in the protoscolex tegument and on the germinal layer of
cyst wall, named EgTeg. However, EgTeg, similarly to AgB,
inhibitschemotaxisandinducesIL-4-positiveTlymphocytes
and noncomplement-ﬁxing antibodies (IgG4) [60].
CE shares with other helmintiases three responses typical
of immediate hypersensitivity reactions such as elevated
IgE/IgG4 antibodies production, eosinophilia, and mastoc-
itosis, which contribute to trigger a Th2-type environment.
By screening an E. granulosus cDNA library with IgE from
patients with CE with acute cutaneous allergic manifes-
tations have been identiﬁed three conserved constitutive
proteins: EgEF-1 β/δ, EA21, and Eg2HSP70 associated with
allergic disorders related to CE [61–63].
The hygiene hypothesis arose from attempts to explain
diﬀerences in allergy prevalence related to socioeconomic
and geographical factors. An inverse relationship between
helminthiasis and allergy has been clearly established despite
both conditions being accompanied by strong Th2 immune
responses. [64]. The CE example stresses the ambiguous
links that exist between parasitic and allergic diseases, and
shows how studying these disease can help to understand
how immune deviation leads to pathological events and to
ﬁnd new immunomodulatory or preventive drugs or both
[64].
4. Concluding Remarks andFutureDirections
Despite the large eﬀorts that have been put into the research
and control of echinococcosis, it still remains a disease of
worldwide signiﬁcance. In some areas of the world, CE
caused by E. granulosus is a re-emerging disease in places
where it was previously at low levels. Although ultrasound
images and benzoimidazole carbamates are very useful in the
clinical treatment of CE, achieving complete healing of the
infection require deﬁning more clearly the immunological
events that accompany changes in cyst morphology.
Exposure to Helminths may protect from immune-
mediated diseases and this evidence suggests that Helminths
may have served as a lid on a “Pandora’s box” of immune
pathology. E. granulosus has evolved to live within its mam-
malian host, and in order to do so appear to express a diverse
array of molecules that have immune-modulating eﬀects.
These observations suggest that E. granulosus molecules
could be used therapeutically to treat or prevent immune-
mediated disease.
Future studies understanding the mechanisms of E.
granulosusimmuneregulation,willpotentiallyuncovernovel
compounds that alter inﬂammatory responses, and will
address the myriad of questions surrounding their potential
for clinical application.
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